Proactive Investors - Run By Investors For Investors

Supreme Pharmaceuticals set to ink cannabis genetics supply deal

It has agreed in principle to supply a Canadian licensed producer with multiple premium cannabis cultivars, or specifically cultivated strains of cannabis
Cannabis farm.
The genetics business diversifies Supreme's revenue base

Supreme Pharmaceuticals Inc (CVE:SL) is set to ink a deal that will see it extend its previously announced diversification to encompass a business-to-business model.

It has agreed in principle to supply a Canadian licensed producer with multiple premium cannabis cultivars for production by the licensed producer, subject to obtaining applicable regulatory approvals, execution of definitive agreements and other customary closing conditions.

If all goes well, the transaction should complete within the next 60 days.

"Last month, we announced the commencement of our business-to-business sales model by entering into letters of intent for the sale of dried marijuana to five fully licensed Canadian licensed producers. Today marks the commencement of the second leg of our business: supply of high-quality cannabis genetics to other licensed producers,” said John Fowler, chief executive officer of Supreme.

“The genetics business diversifies our revenue while remaining committed to supporting the aggregate growth of the legal cannabis industry in Canada," Fowler added.

Shares in Supreme were unchanged on the news.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full SL profile View Profile

Supreme Pharmaceuticals Timeline

Related Articles

April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
Scientist conducting work
CaPre, a potent form of Omega-3, has been shown to reduce triglycerides, but also lower 'bad cholesterol' levels, and raise 'good' ones
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use